Effect of Psiguavin for Obesity Treatment (PSIGUAVIN)

Condition(s) studied

Investigational drug(s) / intervention(s)

Psiguavin: A purified guava extract will be used, enriched in psiguavin

Placebo: Capsules with the same characteristics that Psiguavin intervention but filled with a placebo compound

Study summary

The main objective of the project focuses on the study of the effectiveness of a functional component extracted from Psidium guava, psiguavin, as a potential inhibitor of pancreatic lipase and, therefore, as an adjuvant for the treatment of obesity.

That is, the aim is to verify from various experimental perspectives the effect of psiguavin on the activity of the enzyme pancreatic lipase (EC 3.1.1.3), which is the main enzyme responsible for the digestion of lipids from the diet. Our preliminary studies have shown that there is a strong interaction between psiguavin and the active center of pancreatic lipase; however, it is necessary to confirm these initial hypotheses through a clinical trial. Taking into account that the usefulness of this compound is based on the reduction of dietary calorie intake, in order to confirm its therapeutic usefulness, a clinical trial will be proposed.

To this end, the following specific objective is defined, which is intended to be achieved with the execution of the project:

• Evaluate the effect of psiguavin on weight loss of people with overweight/obese people.

Eligibility

Primary outcome measure(s)

• Percentage of body weight loss — At three months from baseline and after one-year of follow-up
  It will be calculated by subtracting the initial weight less to the final weight, divided by the initial weight and multiplied by 100.
• Percentage of body fat loss — At three months from baseline and after one-year of follow-up
  Meaured by impedance, the change in final fat percentage with respect to the initial value will be calculated.

Trial sites (1)

More Universidad Católica San Antonio de Murcia trials in Spain

Other trials for the same condition